Preferred Label : idelalisib;

MeSH note : an antineoplastic agent and p110delta inhibitor; structure in first source;

CISMeF synonym : CAL 101; GS-1101;

MeSH hyponym : CAL101; CAL-101;

Is substance : O;

UNII : YG57I8T5M0;

InChIKey : IFSDAJWBUCMOAH-HNNXBMFYSA-N;

Details


Main resources

You can consult :


https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig-idelalisib-antineoplasique
https://www.has-sante.fr/portail/jcms/c_2774117/fr/zydelig
2018
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
Rituximab
continuity of patient care
pneumonia, pneumocystis
neutropenia
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
Summary Safety Review - Zydelig (idelalisib) - Assessing the potential risk of serious infections
http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/zydelig-fra.php
2017
false
false
false
Canada
French
English
idelalisib
idelalisib
canada
administration, oral
antineoplastic agents
risk assessment
drug evaluation
Infections
Infections
pharmacovigilance note
purines
quinazolinones

---
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/57590a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
canada
antineoplastic combined chemotherapy protocols
antineoplastic agents
idelalisib
early termination of clinical trials
idelalisib
purines
quinazolinones

---
http://www.has-sante.fr/portail/jcms/c_2628549/fr/zydelig
2016
false
false
false
France
French
treatment outcome
purines
quinazolinones
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
evaluation of the transparency committee
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
chromosome 17 deletion
phosphatidylinositol 3-Kinases
Smith-Magenis syndrome
chromosome deletion
chromosomes, human, pair 17
Phosphoinositide-3 Kinase Inhibitors

---
ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58118a-fra.php
2016
false
false
false
Canada
French
English
survival analysis
idelalisib
idelalisib
leukemia, lymphocytic, chronic, B-Cell
risk assessment
antineoplastic agents
cause of death
Infections
antineoplastic combined chemotherapy protocols
Rituximab
continuity of patient care
pneumonia, pneumocystis
sepsis
cytomegalovirus infections
Chemotherapy-Induced febrile neutropenia
pharmacovigilance note
lymphoma, Non-Hodgkin
Indolent Non-Hodgkin Lymphoma
purines
quinazolinones

---
http://www.has-sante.fr/portail/jcms/c_2047021/fr/zydelig-idelalisib-inhibiteur-de-kinase
2015
false
false
false
France
French
treatment outcome
purines
purines
quinazolinones
quinazolinones
antineoplastic agents
antineoplastic agents
administration, oral
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
antineoplastic combined chemotherapy protocols
adult
idelalisib
idelalisib
idelalisib
evaluation of the transparency committee
guidelines for drug use
Loss of Chromosome 17p
leukemia, lymphocytic, chronic, B-Cell
mutation
genes, p53
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
https://www.ema.europa.eu/medicines/human/EPAR/Zydelig
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
purines
purines
quinazolinones
quinazolinones
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
tablets
leukemia, lymphocytic, chronic, B-Cell
lymphoma, follicular
enzyme inhibitors
enzyme inhibitors
PIK3CB protein, human
product surveillance, postmarketing
antineoplastic combined chemotherapy protocols
adult
drug interactions
pregnancy
breast feeding
idelalisib
drug evaluation, preclinical
idelalisib
idelalisib
Idelalisib/Rituximab Regimen
phosphatidylinositol 3-Kinases
Phosphoinositide-3 Kinase Inhibitors
Phosphoinositide-3 Kinase Inhibitors

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.